Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
silncRNA16
- Development stage
- Preclinical
- Lead developer
- Sichuan University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
silncRNA16 is an experimental small interfering RNA (siRNA) therapeutic designed to target and silence **long non-coding RNA 16 (lncRNA16)**, also known as lnc-HC. Research, primarily conducted at **Sichuan University**, has identified lncRNA16 as a critical regulator of lipid metabolism and inflammatory responses in the context of **atherosclerosis**. By utilizing RNA interference (RNAi) to degrade lncRNA16, silncRNA16 aims to modulate the expression of downstream genes such as **ATP-binding cassette transporter A1 (ABCA1)** and **Cholesterol 7-alpha-hydroxylase (CYP7A1)**. These modifications promote cholesterol efflux from macrophages and enhance bile acid synthesis, thereby reducing lipid accumulation in the arterial wall and inhibiting the progression of atherosclerotic plaques. silncRNA16 is currently being investigated in preclinical models as a potential treatment for atherosclerosis and hyperlipidemia.
- Other names
- si-lncRNA16si-lncRNA-16si-lncRNA 16siRNA targeting lncRNA16
02
Targets
SNHG1
Beyond the preview
Go deeper on silncRNA16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on silncRNA16.